Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects
Animal research · 1996
- What was studied
- Mouse hepatic-enzyme screening and sensitized guinea-pig anaphylaxis experiments
- Main finding
- ADK-559/591/676/677 weakly inhibited hepatic monooxygenases; ADK-709/790/828/829/910/918 induced P450. The author also reports fewer anaphylaxis deaths with ADK-828 and ADK-829 in guinea pigs. Different controls and OCR table ambiguities prevent a reliable cross-compound ranking.
Study data at a glance
- Participants or experimental model
- Mouse hepatic-enzyme screening and sensitized guinea-pig anaphylaxis experiments
- Reported results
- ADK-559/591/676/677 weakly inhibited hepatic monooxygenases; ADK-709/790/828/829/910/918 induced P450. The author also reports fewer anaphylaxis deaths with ADK-828 and ADK-829 in guinea pigs. Different controls and OCR table ambiguities prevent a reliable cross-compound ranking.
Study limitations and source details
Study limitations
- Original structures and tables require checking against the scan; transcription errors are possible.
- Enzyme induction does not establish detoxification benefits or predict safe human drug combinations.
- Animal anaphylaxis results are not evidence for treating allergy in people; proposed adjunct uses were development suggestions.
Source details
Dissertation; OCR reproduction · Dissertation abstract transcription
Selected source passages checked; complete methods and risk of bias not appraised.
Sources checked
Citation
T. G. Khlopushina. Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects Doctoral dissertation author’s abstract. Moscow, 1996
Related compounds
Bromantane
A synthetic adamantane drug, also called Ladasten, studied in Russian fatigue and stress research.
Chlodantane
N-(adamantan-2-yl)-4-chlorobenzamide (ADK-910), an experimental small molecule with an adamantane cage joined to a chlorobenzamide. Russian studies examined temperature stress and physical workload.
ADK-918
The para-bromobenzamide counterpart of Chlodantane, N-(adamantan-2-yl)-4-bromobenzamide. It is chemically distinct from Bromantane.
ADK-559
ADK-559 is an experimental N-substituted adamantylpiperazine. A historical screen reported weak inhibition of hepatic monooxygenases, enzymes involved in drug metabolism. The source does not identify the N-substituent.
ADK-591
ADK-591 is an experimental N-substituted adamantylpiperazine. A historical screen reported weak inhibition of hepatic monooxygenases, enzymes involved in drug metabolism. The source does not identify the N-substituent.
ADK-676
ADK-676 is an experimental N-substituted adamantylpiperazine. A historical screen reported weak inhibition of hepatic monooxygenases, enzymes involved in drug metabolism. The source does not identify the N-substituent.
ADK-677
ADK-677 is an experimental N-substituted adamantylpiperazine. A historical screen reported weak inhibition of hepatic monooxygenases, enzymes involved in drug metabolism. The source does not identify the N-substituent.
ADK-790
An experimental adamantane–benzimidazole compound studied for its effects on liver enzymes that metabolize drugs.
ADK-828
Adamantylidene-2,6-diacetonitrile, an experimental adamantane derivative. Animal studies examined induction of liver drug-metabolizing enzymes and anaphylactic reactions.
ADK-829
An experimental bromophenyl benzamide attached to an adamantane group, identified in a historical liver-enzyme screen.